Hepatocellular Carcinoma
📧 Sign up to get email alerts when something new happens for Hepatocellular Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-02-19Clinical Trial Update: BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma [Phase 1, Phase 2]
Withdrawn Phase 1/2 clinical trial of BC3402 in combination with tremelimumab and durvalumab (STRIDE) for hepatocellular carcinoma.
-
CLINICAL_TRIALS withdrawal · 2026-02-18Clinical Trial Update: Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment [Phase 1]
A Phase 1 study of NP-101 in patients with unresectable hepatocellular carcinoma undergoing Y-90 treatment has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-11-18Clinical Trial Update: A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma [Phase 2]
The trial PRISM evaluating preoperative irradiation with tremelimumab and ongoing durvalumab for resectable/advanced hepatocellular carcinom…
-
CLINICAL_TRIALS withdrawal · 2025-09-11Clinical Trial Update: A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies [Phase 2]
A Phase II clinical trial investigating adjuvant immunotherapy targeting KRAS G12D, KRAS G12V, and TP53 R175H across several gastrointestina…
-
CLINICAL_TRIALS withdrawal · 2025-08-12Clinical Trial Update: A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC). [Phase 1]
Phase 1 trial evaluating TQB2618 with Penpulimab and Anlotinib for first-line advanced hepatocellular carcinoma has been terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-05-23Clinical Trial Update: Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC [Phase 2]
Phase 2 trial evaluating cadonilimab plus lenvatinib as second-line treatment for unresectable hepatocellular carcinoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-04-27Clinical Trial Update: A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma [Phase 2]
A Phase II study of ABC294640 as monotherapy in advanced hepatocellular carcinoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-03-24Clinical Trial Update: Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions of Primary Hepatocellular Carcinoma [NA]
Clinical trial NCT03636607 evaluating 18F-FDG PET/CT dynamic imaging and genomic sequencing for detecting metastatic lesions in hepatocellul…
-
CLINICAL_TRIALS withdrawal · 2025-03-18Clinical Trial Update: A Pilot Study For Patients Receiving Radiation Therapy for Liver Cancer [NA]
A pilot trial evaluating radiation therapy for hepatocellular carcinoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-03-18Clinical Trial Update: TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors [Phase 1, Phase 2]
Tarus Therapeutics has withdrawn its TT-4 single-agent trial in advanced solid tumors across Phase 1 and Phase 2. The listed conditions incl…
-
CLINICAL_TRIALS withdrawal · 2025-03-11Clinical Trial Update: Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC) [Phase 1, Phase 2]
A Phase 1/2 trial of chidamide plus regorafenib for hepatocellular carcinoma has been terminated.
-
CLINICAL_TRIALS withdrawal · 2025-02-05Clinical Trial Update: Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy for Primary Liver Malignancies [Phase 4]
A Phase 4 trial assessing the Surefire Infusion Device in regional intra-arterial therapy for primary liver malignancies has been withdrawn.…
-
CLINICAL_TRIALS withdrawal · 2024-11-25Clinical Trial Update: Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
A Travera Inc clinical trial (NCT04985357) evaluating mass response as a biomarker for tumor sensitivity to drugs has been withdrawn; no res…
-
CLINICAL_TRIALS withdrawal · 2024-11-25Clinical Trial Update: A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona [NA]
This clinical trial evaluating a social support intervention for Hispanic patients with renal cell carcinoma or hepatocellular carcinoma in …
-
CLINICAL_TRIALS withdrawal · 2024-11-22Clinical Trial Update: TATE Versus TACE in Intermediate Stage HCC [Phase 2]
A Phase 2 trial comparing TATE to transarterial chemoembolization in intermediate-stage hepatocellular carcinoma has been terminated.
-
CLINICAL_TRIALS withdrawal · 2024-09-04Clinical Trial Update: A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma [Phase 2]
A Phase 2 trial evaluating TAC-101 in combination with transarterial chemoembolization (TACE) versus TACE alone in Asian patients with hepat…
-
CLINICAL_TRIALS withdrawal · 2024-08-29Clinical Trial Update: Treat-and-resect Study of Echo Decorrelation Imaging-controlled Radiofrequency Ablation in Liver Tumors [NA]
The treat-and-resect study of Echo Decorrelation Imaging–controlled Radiofrequency Ablation for liver tumors has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-08-26Clinical Trial Update: A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma [Phase 1, Phase 2]
A Phase 1/2 study evaluating atezolizumab, bevacizumab, and ADI-PEG 20 for locally advanced or metastatic hepatocellular carcinoma has been …
-
CLINICAL_TRIALS withdrawal · 2024-08-09Clinical Trial Update: Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC) [Phase 1]
A Phase 1 trial evaluating INCBB099280 as a pre-transplant therapy for hepatocellular carcinoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-07-31Clinical Trial Update: Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels [Phase 2]
Phase 2 study evaluating chemotherapy with or without sequential cytoreductive surgery for metastatic foregut cancer with undetectable circu…
-
CLINICAL_TRIALS withdrawal · 2023-06-07Clinical Trial Update: Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma [Phase 3]
Phase 3 trial evaluating sitravatinib plus tislelizumab vs controls in hepatocellular carcinoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2023-05-03Clinical Trial Update: Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery [Phase 4]
A Phase 4 clinical trial evaluating anesthetic agents and acute kidney injury after liver resection has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2022-05-05Clinical Trial Update: A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC [Phase 3]
A Phase 3 trial comparing HLX10+HLX04 to sorafenib as first-line treatment in hepatocellular carcinoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2020-09-14Clinical Trial Update: HepATocellular Cancer Hcv Therapy Study [Phase 3]
Phase 3 trial for hepatocellular carcinoma/HCV therapy has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2020-01-09Clinical Trial Update: Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection [Phase 2, Phase 3]
A clinical trial evaluating lenvatinib plus nivolumab vs lenvatinib for advanced hepatocellular carcinoma with HBV infection was withdrawn.